Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

Background Imatinib mesylate, an inhibitor of KIT, ABL protein, and platelet-derived growth factor receptor α (PDGFRα) tyrosine kinase, has recently been found to have a dramatic antitumor effect on gastrointestinal stromal tumor (GIST). The aim of this study was to assess the efficacy and safety of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2008-06, Vol.13 (3), p.244-251
Hauptverfasser:	Nishida, Toshirou, Shirao, Kuniaki, Sawaki, Akira, Koseki, Masato, Okamura, Takeshi, Ohtsu, Atsushi, Sugiyama, Toshiro, Miyakawa, Kunihisa, Hirota, Seiichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Cancer Cancer Research Chemotherapy Clinical outcomes Clinical trials Disease-Free Survival Female Gastrointestinal diseases Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - mortality Gastrointestinal Stromal Tumors - pathology Humans Imatinib Mesylate Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Piperazines - adverse effects Piperazines - pharmacokinetics Piperazines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Surgical Oncology Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!